[Dendritic cells and gliomas: a hope in immunotherapy?].
Immunotherapy has been explored for several decades to try to improve the prognosis of gliomas, but until recently no therapeutic benefit has been achieved. The discovery of dendritic cells, the most potent professional antigen presenting cells to initiate specific immune response, and the possibility of producing them ex vivo gave rise to new protocols of active immunotherapy. In oncology, promising experimental and clinical therapeutic results were obtained using these dendritic cells loaded with tumor antigen. Patients bearing gliomas have deficit antigen presentation making this approach rational. In several experimental glioma models, independent research teams have showed specific antitumor responses using these dendritic cells. Phase I/II clinical trials have demonstrated the feasibility and the tolerance of this immunotherapeutic approach. In neuro-oncology, the efficiency of such an approach remains to be established, similarly in oncology where positive phase III studies are missing. Nevertheless, dendritic cells comprise a complex network which is only partially understood and capable of generating either immunotolerance or immune response. Numerous parameters remain to be explored before any definitive conclusion about their utility as an anticancer weapon can be drawn. It seems however logical that immunotherapy with dendritic cells could prevent or delay tumor recurrence in patients with minor active disease. A review on glioma and dendritic cells is presented.
Jouanneau
E
E
Service de Neurochirurgie (Pr. M. Sindou et Pr. G. Perrin), Hôpital Neurologique et Neurochirurgical Pierre-Wertheimer, Université Claude-Bernard - Lyon I, 59, boulevard Pinel, 69394 Lyon Cedex 03. emmanuel.jouanneau@chu-lyon.fr
Poujol
D
D
Caux
C
C
Belin
M-F
MF
Blay
J-Y
JY
Puisieux
I
I
D000938:Antigen-Presenting Cells / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D001932:Brain Neoplasms / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D005910:Glioma / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D018448:Models, Immunological
D000951:Antigens, Neoplasm